Zimmer Biomet Holdings, Inc. (ZBH) Shares Bought by QCI Asset Management Inc. NY

QCI Asset Management Inc. NY raised its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 2.0% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 132,504 shares of the medical equipment provider’s stock after purchasing an additional 2,623 shares during the period. Zimmer Biomet Holdings accounts for approximately 1.7% of QCI Asset Management Inc. NY’s holdings, making the stock its 21st biggest holding. QCI Asset Management Inc. NY owned 0.07% of Zimmer Biomet Holdings worth $15,515,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in ZBH. Greenwood Gearhart Inc. increased its position in shares of Zimmer Biomet Holdings by 1.9% in the 1st quarter. Greenwood Gearhart Inc. now owns 39,329 shares of the medical equipment provider’s stock worth $4,802,000 after purchasing an additional 718 shares during the last quarter. Lincluden Management Ltd. increased its position in shares of Zimmer Biomet Holdings by 14.5% in the 1st quarter. Lincluden Management Ltd. now owns 59,329 shares of the medical equipment provider’s stock worth $7,245,000 after purchasing an additional 7,492 shares during the last quarter. FNY Partners Fund LP bought a new stake in shares of Zimmer Biomet Holdings in the 1st quarter worth about $249,000. Point72 Asset Management L.P. increased its position in shares of Zimmer Biomet Holdings by 230.3% in the 1st quarter. Point72 Asset Management L.P. now owns 1,053,500 shares of the medical equipment provider’s stock worth $128,643,000 after purchasing an additional 734,500 shares during the last quarter. Finally, Bank of Nova Scotia increased its position in shares of Zimmer Biomet Holdings by 933.9% in the 1st quarter. Bank of Nova Scotia now owns 45,996 shares of the medical equipment provider’s stock worth $5,616,000 after purchasing an additional 41,547 shares during the last quarter. 85.44% of the stock is owned by institutional investors.

Shares of Zimmer Biomet Holdings, Inc. (NYSE ZBH) traded down $1.09 during trading hours on Monday, hitting $110.75. 973,400 shares of the stock were exchanged, compared to its average volume of 1,366,571. The firm has a market cap of $22,390.00, a price-to-earnings ratio of 13.72, a P/E/G ratio of 1.72 and a beta of 1.17. Zimmer Biomet Holdings, Inc. has a 12 month low of $95.63 and a 12 month high of $133.49. The company has a current ratio of 1.47, a quick ratio of 0.78 and a debt-to-equity ratio of 0.88.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $1.72 earnings per share for the quarter, missing analysts’ consensus estimates of $1.74 by ($0.02). The company had revenue of $1.82 billion during the quarter, compared to analyst estimates of $1.83 billion. Zimmer Biomet Holdings had a return on equity of 16.29% and a net margin of 8.36%. The company’s revenue was down .8% on a year-over-year basis. During the same period in the prior year, the company posted $1.79 earnings per share. equities analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.03 earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: This piece of content was originally published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are accessing this piece of content on another site, it was stolen and republished in violation of international copyright and trademark law. The correct version of this piece of content can be accessed at https://www.chaffeybreeze.com/2017/11/13/zimmer-biomet-holdings-inc-zbh-shares-bought-by-qci-asset-management-inc-ny.html.

A number of equities research analysts recently weighed in on ZBH shares. Zacks Investment Research downgraded shares of Zimmer Biomet Holdings from a “hold” rating to a “strong sell” rating in a research report on Tuesday, August 8th. BMO Capital Markets lowered their price objective on shares of Zimmer Biomet Holdings from $140.00 to $135.00 and set an “outperform” rating for the company in a research report on Thursday, November 2nd. Jefferies Group LLC reaffirmed a “buy” rating and set a $136.00 price objective on shares of Zimmer Biomet Holdings in a research report on Friday, November 3rd. Royal Bank Of Canada lowered their price objective on shares of Zimmer Biomet Holdings to $125.00 and set an “outperform” rating for the company in a research report on Tuesday, November 7th. Finally, Morgan Stanley boosted their price objective on shares of Zimmer Biomet Holdings from $137.00 to $150.00 and gave the company an “overweight” rating in a research report on Monday, July 17th. Four investment analysts have rated the stock with a sell rating, seven have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $134.00.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH).

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply